Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
221 stopped studies mapped to Malignant Skin Neoplasm and descendants · 91% state a reason
Over the 221 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06568172 | Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the… | Phase 3 | suspended | Aug 23, 2024 | National Cancer Institute (NCI) | Other - Other | Other (stated, no rule matched) |
| NCT06990737 | Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically… | Phase 2 | withdrawn | May 25, 2025 | University of California, Davis | Poor accrual | Enrollment / accrual |
| NCT07042295 | Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in… | Phase 2 | suspended | Jun 29, 2025 | National Cancer Institute (NCI) | Other - planned analysis of safety and efficacy data | Safety / toxicity |
| NCT02702310 | Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed… | — | suspended | Mar 8, 2016 | Vanderbilt-Ingram Cancer Center | Treatment unavailable at facility | Other (stated, no rule matched) |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT04221438 | Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph… | Phase 2 | terminated | Jan 9, 2020 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT03384836 | Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV… | Phase 1 / Phase 2 | suspended | Dec 27, 2017 | Roswell Park Cancer Institute | interim Analysis | Efficacy / futility |
| NCT06470451 | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL(FLASH2) | Phase 3 | terminated | Jun 24, 2024 | Soligenix | The Data Monitoring Committee conducted an interim analysis and recommended that the study be… | Efficacy / futility |
| NCT06984328 | Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to… | Phase 2 | terminated | May 22, 2025 | Genmab | Genmab has decided to discontinue further clinical development of acasunlimab following strategic… | Safety / toxicity |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Phase 1 | terminated | Oct 7, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns. | Safety / toxicity |
| NCT05050162 | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation… | Phase 2 / Phase 3 | suspended | Sep 20, 2021 | NRG Oncology | End of Initial Phase of Multi-phase protocol; closed for protocol specified analysis | Other (stated, no rule matched) |
| NCT07100925 | A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk… | Phase 1 | withdrawn | Aug 3, 2025 | Ankyra Therapeutics, Inc | Strategic realignment | Sponsor / business decision |
| NCT04734704 | Defining the Role of the Skin Microbiome in Immune-related Adverse Events(SKINBIOTA) | N/A | terminated | Feb 2, 2021 | University Hospital, Bordeaux | target number of patients not reached and disabling team changes | Other (stated, no rule matched) |
| NCT04702854 | Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma(BMUMM) | N/A | terminated | Jan 11, 2021 | Centre Hospitalier Universitaire de Nice | recruitment challenges | Enrollment / accrual |
| NCT05414500 | Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides | Phase 1 | suspended | Jun 10, 2022 | University of Alabama at Birmingham | IRB audit | Other (stated, no rule matched) |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In… | Phase 2 | terminated | Jun 7, 2021 | Regeneron Pharmaceuticals | Sponsor Decision related to study drug supply | Drug supply |
| NCT05110781 | Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck… | Phase 2 | terminated | Nov 8, 2021 | University of California, Davis | Slow accrual | Enrollment / accrual |
| NCT06391099 | Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With… | N/A | suspended | Apr 30, 2024 | Ohio State University Comprehensive Cancer Center | pending amendment | Other (stated, no rule matched) |
| NCT02943642 | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With…(Resimmune®) | Phase 2 | withdrawn | Oct 25, 2016 | Virogen Biotechnology Inc. | This record is an earlier version (crossover design). After FDA-approved IND sponsor transfer to… | Other (stated, no rule matched) |
| NCT06379581 | Skin Cancer Diagnostics Using Photoacoustic Imaging | — | suspended | Apr 23, 2024 | Region Skane | Lack of available personnel for recruitment of patients. | Enrollment / accrual |
| NCT04064424 | Cancer Prevention & Online Technologies | N/A | withdrawn | Aug 21, 2019 | Stanford University | Zero participants enrolled | Enrollment / accrual |
| NCT03699995 | MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma | N/A | terminated | Oct 9, 2018 | OHSU Knight Cancer Institute | The study did not meet its accrual goals due to the departure of study personnel. Study team opted… | Enrollment / accrual |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and… | Phase 1 | terminated | Feb 5, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05956795 | Surveillance of Regional Nodal Basins in Patients With Primary High Risk Cutaneous… | — | terminated | Jul 21, 2023 | Johns Hopkins University | Expired in IRB | Other (stated, no rule matched) |
| NCT03716193 | Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron… | N/A | terminated | Oct 23, 2018 | West Virginia University | Terminated March 22, 2022 due to COVID-19 pandemic | COVID-19 / pandemic |
| NCT06235281 | Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)(PLIGHT) | Early Phase 1 | suspended | Jan 31, 2024 | H. Lee Moffitt Cancer Center and Research Institute | Slow Accrual | Enrollment / accrual |
| NCT04913220 | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With… | Phase 1 / Phase 2 | terminated | Jun 4, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Safety / toxicity |
| NCT04163952 | Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or… | Phase 1 | terminated | Nov 15, 2019 | Rutgers, The State University of New Jersey | slow accrual | Enrollment / accrual |
| NCT05846724 | Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma(PULSAR) | Phase 2 | withdrawn | May 6, 2023 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | The lack of adequate funding has made it impossible to continue with the clinical study As this… | Funding |
| NCT05321784 | At-Home Dermoscopy Artificial Intelligence | N/A | terminated | Apr 11, 2022 | OHSU Knight Cancer Institute | Inadequate enrollment | Enrollment / accrual |
| NCT03886181 | Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial… | N/A | terminated | Mar 22, 2019 | Alpha Tau Medical LTD. | Difficulties in recruitment and the site's resources to recruit patients | Enrollment / accrual |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT03901573 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | Phase 1 / Phase 2 | terminated | Apr 3, 2019 | NeoImmuneTech | Strategic decision by sponsor | Sponsor / business decision |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04541017 | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual… | Phase 1 / Phase 2 | terminated | Sep 9, 2020 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05879458 | Ritlecitinib in CTCL | Phase 2 | terminated | May 30, 2023 | Icahn School of Medicine at Mount Sinai | No significant improvement in disease as graded by our assessments. | Other (stated, no rule matched) |
| NCT03737721 | The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and…(UNSCARRed) | Phase 2 | terminated | Nov 9, 2018 | AHS Cancer Control Alberta | Loss of Pharma Support | Other (stated, no rule matched) |
| NCT05538988 | BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd…(BIOSELECT) | Phase 1 / Phase 2 | withdrawn | Sep 14, 2022 | AHS Cancer Control Alberta | Contractual Issues | Other (stated, no rule matched) |
| NCT03325101 | Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma | Phase 1 / Phase 2 | terminated | Oct 30, 2017 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT05106192 | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel… | N/A | withdrawn | Nov 3, 2021 | Case Comprehensive Cancer Center | Study closed prior to enrollment of first participant | Enrollment / accrual |
| NCT04830124 | Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With…(ARTISTRY-6) | Phase 2 | terminated | Apr 2, 2021 | Mural Oncology, Inc | Study terminated due to business and strategic decision. | Sponsor / business decision |
| NCT04099446 | A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer | — | withdrawn | Sep 23, 2019 | ProgenaBiome | Sponsor decision | Sponsor / business decision |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With… | Phase 1 | terminated | Feb 14, 2018 | Mayo Clinic | funding - sponsor filing Chapter 11 bankruptcy | Funding |
| NCT04329221 | Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant… | Phase 2 | withdrawn | Apr 1, 2020 | Massachusetts General Hospital | The study was withdrawn due to lack of financial support. | Funding |
| NCT04642287 | Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant… | Phase 2 | withdrawn | Nov 24, 2020 | Massachusetts General Hospital | The study was withdrawn due to lack of financial support. | Funding |
| NCT02548468 | Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in… | Phase 1 | withdrawn | Sep 14, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT06644079 | Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell… | Phase 2 | withdrawn | Oct 16, 2024 | University of Florida | Study not moving forward due to upcoming PI departure | Other (stated, no rule matched) |
| NCT03288818 | Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel… | Phase 2 | withdrawn | Sep 20, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Funding discontinued | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials